Sulfadiazine Toxicity — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for sulfadiazine toxicity. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2039. Daily refresh.

1
Approved drugs
2
Active US patents
50/100
Avg vulnerability
—
Annual revenue covered

Originators in Sulfadiazine Toxicity

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Acrotech Biopharma 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating sulfadiazine toxicity. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Fusilev
levoleucovorin
 Acrotech Biopharma 2 50 — 2039-03-25

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11541012 Fusilev formulation 50 2039-03-25
11541012 Fusilev formulation 50 2039-03-25

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11541012 Fusilev formulation 50 2039-03-25
11541012 Fusilev formulation 50 2039-03-25

Related